You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in Boston (Radium-223, Pembrolizumab)

Active, not recruiting
Has Results
  • Prostate Cancer
  • Boston, Massachusetts
  • +1 more
Aug 31, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Cabozantinib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Salt Lake City, Utah
    Huntsman Cancer Institute at University of Utah
Nov 10, 2022

Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC Trial (INKmune)

Not yet recruiting
  • Cancer
  • +2 more
  • INKmune
  • (no location specified)
Sep 27, 2023

Metastatic Castration-resistant Prostate Cancer Trial in United Kingdom, United States (PLX2853, Olaparib, Abiraterone acetate)

Terminated
  • Metastatic Castration-resistant Prostate Cancer
  • Chicago, Illinois
  • +7 more
Oct 4, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Tianjin (TABP EIC, Cyclophosphamide, fludarabine)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • TABP EIC
  • +2 more
  • Tianjin, China
    Tianjin pepole's hosptial
Jul 28, 2022

Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco

Not yet recruiting
  • Castrate Resistant Prostate Cancer
  • +3 more
  • San Francisco, California
    University of California, San Francisco
Mar 1, 2023

Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • ONC-392
  • lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
  • (no location specified)
Dec 27, 2022

Prostate Cancer Castration-resistant Prostate Cancer Trial in Changsha (Abiraterone+SHR3162)

Active, not recruiting
  • Prostate Cancer Castration-resistant Prostate Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Jul 6, 2022

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory

Active, not recruiting
Has Results
  • Castration Levels of Testosterone
  • +9 more
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
  • +2 more
Apr 4, 2022

Metastatic Castration-resistant Prostate Cancer Trial (ONCT-534)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Jun 15, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Mexico City (SV-102)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Mexico City, Mexico
    Hospital Diomed
Sep 14, 2022

Metastatic Castration-resistant Prostate Cancer Trial in United States (BMS-986460)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Palo Alto, California
  • +7 more
Oct 10, 2023

Prostate Cancer Trial in Beijing, Nanjing (QLH12016)

Not yet recruiting
  • Prostate Cancer
  • Beijing, Beijign, China
  • +1 more
Jul 25, 2023

Metastatic Castration Resistant Prostate Cancer (mCRPC) Trial (Pidnarulex, Talazoparib)

Not yet recruiting
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • (no location specified)
Jun 15, 2022

Prostatic Tumors, Castration-Resistant Trial in Leiden (Patient-specific adaptive therapy, Abiraterone acetate, Enzalutamide)

Recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • Patient-specific adaptive therapy
  • +2 more
  • Camperdown, New South Wales, Australia
  • +6 more
Jan 11, 2023

Prostate Cancer, Castrate Resistant Prostate Cancer Trial (Enzalutamide 40 MG, Docetaxel injection)

Not yet recruiting
  • Prostate Cancer
  • Castrate Resistant Prostate Cancer
  • Enzalutamide 40 MG
  • Docetaxel injection
  • (no location specified)
Jan 27, 2023

Patients and Other Factors Which May Contribute to Survival

Completed
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Radium-223 dichloride (Xofigo, BAY88-8223)
  • Whippany, New Jersey
    Bayer Flatiron Xofigo Registry database
Mar 17, 2022

Prostate Cancer Trial in Ann Arbor, Detroit, Charlottesville (Olaparib, AZD6738)

Active, not recruiting
  • Prostate Cancer
  • Ann Arbor, Michigan
  • +2 more
Jan 9, 2023

Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Boston (Talazoparib, Tazemetostat)

Recruiting
  • Metastatic Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Boston, Massachusetts
  • +1 more
Jul 18, 2022

Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Boston (Abemaciclib, Atezolizumab)

Recruiting
  • Prostate Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 26, 2022

Prostate Cancer Metastatic Trial in New York, Knoxville (HB-302/HB-301 Alternating 2-Vector Therapy)

Recruiting
  • Prostate Cancer Metastatic
  • HB-302/HB-301 Alternating 2-Vector Therapy
  • New York, New York
  • +1 more
Feb 1, 2023

Prostate-Specific Membrane Antigen (PSMA) Radionuclide Therapy

Recruiting
  • PSMA-positive Metastatic Castration-resistant Prostate Cancer Treated With PSMA Radionuclide Therapy
  • PSMA radionuclide therapy
  • Dallas, Texas
    Methodist Dallas Medical Center
Aug 9, 2023

Prostate Cancer Metastatic Trial in United States (FOR46)

Active, not recruiting
  • Prostate Cancer Metastatic
  • Los Angeles, California
  • +4 more
May 9, 2022

Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

Not yet recruiting
  • Androgen-Independent Prostatic Cancer
  • +8 more
  • lorigerlimab
  • +2 more
  • (no location specified)
May 4, 2023

Prostatic Tumors, Castration-Resistant Trial in Brisbane ([212Pb]Pb-ADVC001)

Not yet recruiting
  • Prostatic Neoplasms
  • Castration-Resistant
  • Brisbane, Queensland, Australia
    Royal Brisbane & Women's Hospital
Feb 9, 2023